NexCAR19 Cost and How Families Pay for It

There is no single public list price for NexCAR19. The figure most often quoted is around US$50,000, stated by ImmunoACT co-founder Dr. Atharva Karulkar at the American Society of Hematology meeting in December 2023 and reported by the US National Cancer Institute on 7 February 2024. Indian health writing since then has commonly described a band of roughly ₹30 lakh to ₹40 lakh for the therapy itself.

Two things about that number matter more than its size.

First, it is a course price, not a cycle price. CAR-T is not a repeating infusion. Your own T cells are collected, sent for engineering, and returned to you once. What is priced is the manufacture of a single product, for one person, that nobody else can use. So it cannot be paid down in instalments of treatment the way a chemotherapy or checkpoint-inhibitor course can — and the money question has to be settled before cell collection, not during treatment.

Second, ImmunoACT does not publish a rupee rate card. Its patient material describes NexCAR19 as costing approximately one-tenth of the international price, without naming a figure. Each authorised centre quotes individually, and the quote reflects that centre's own charges as well as the product. The published band is a starting point; only an authorised centre's written estimate is your number.

Figures above are indicative published amounts, as of August 2026, sourced from the US National Cancer Institute's Cancer Currents report of 7 February 2024 and from ImmunoACT's own patient material. They are not a CION price list, not a quote, and CION does not supply this therapy.

By roughly an order of magnitude. The National Cancer Institute reported in February 2024 that a CAR T-cell infusion in the United States costs about US$400,000. Immuneel Therapeutics, which markets India's second approved CAR-T product, states in its published media material that the therapy can cost between US$350,000 and US$700,000 globally. India is unusual in having two domestically approved CD19 CAR-T products in the lower band.

The gap is mostly manufacturing and pricing geography. NexCAR19 was designed at IIT Bombay specifically so that it could be produced in India for the Indian health system, and CDSCO assessed it on Indian trial data. In the trials supporting approval, the National Cancer Institute reported that 26 of 38 evaluable patients with lymphoma and 10 of 15 with leukaemia had an objective response — sourced figures from a small, heavily pre-treated group, not a prediction for any individual.

What the price difference does not tell you is which product suits a given person. That is a clinical decision made at an authorised centre on your diagnosis, CD19 status, prior lines of treatment and general fitness — not a decision to be made on price.

The therapy price covers manufacturing and supplying your CAR-T product. It does not cover the treatment around it. Families who budget only for the headline figure are usually short by a substantial margin, and they discover it at the worst possible moment — after cell collection, when manufacturing has already begun.

Sitting around the product price are:

• Leukapheresis — the day-care procedure in which your T cells are separated out, typically four to six hours.
• Bridging treatment — treatment given during the roughly three to four weeks your cells are being engineered, if the disease needs controlling in the meantime.
• Lymphodepleting chemotherapy — a short course before infusion, usually with a hospital stay of about three days.
• The admission around infusion — the infusion itself is short, but the monitoring afterwards is the point of the admission.
• Management of side effects — cytokine release syndrome and neurological effects are recognised risks of this treatment class and are managed in hospital, sometimes in intensive care, with medicines that are themselves expensive.
• Living near the centre — ImmunoACT's patient guidance asks families to plan for approximately six to ten weeks near the treatment centre in total, and to stay within thirty minutes of it for at least four weeks after infusion, with a caregiver present throughout.
• The costs nobody quotes — travel, accommodation for two people, and lost income for the caregiver as well as the patient. The patient is also advised not to drive for around eight weeks after infusion.

The practical rule is simple. Ask the authorised centre for a written estimate covering the whole pathway, from leukapheresis to the end of the monitoring period, itemised so the product price sits on its own line. A quote showing only the therapy figure is not an estimate you can plan around.

Affording it and being eligible for it are two different questions, and eligibility is the harder one. NexCAR19 is authorised for particular relapsed or refractory B-cell cancers where the CD19 target is present. The overwhelming majority of people with cancer in India are not candidates for it at any price. That has to be said on a cost page, because cost pages are exactly where hope tends to outrun eligibility.

NexCAR19 is generally not an option, or is considered only with specialist caution, for people who:

• have a cancer that is not a B-cell lymphoma or B-cell acute lymphoblastic leukaemia — solid tumours are outside the approved indication entirely, and this is by far the largest group;
• have a B-cell cancer whose cells do not carry CD19 on testing, since that is the target the therapy is built around;
• have not yet had, or have not exhausted, the standard lines of treatment that come before cell therapy in the pathway;
• are outside the approved age range for the specific product — the two Indian products differ here, and the centre will confirm which applies;
• are not well enough overall, or whose heart, lung, liver or kidney function will not tolerate lymphodepleting chemotherapy and the possibility of cytokine release syndrome;
• have an active, uncontrolled infection at the time of the planned treatment;
• are pregnant or breastfeeding — ImmunoACT's patient material states that CAR-T is not recommended in these situations, as safety data is not available;
• cannot arrange a caregiver and accommodation near an authorised centre for the required weeks after infusion, which is a safety requirement rather than a convenience.

None of these are rules to apply to yourself from a web page, and none are reasons to rule yourself out before a specialist has looked. They are the reasons a haematologist may say no to CAR-T even when the money has been found. Only the treating team at an authorised centre, with your pathology, CD19 status, treatment history and current fitness in front of them, can answer whether it applies to you.

No single route covers a CAR-T course. Families who complete treatment almost always assemble the money from several sources at once — insurance where the policy allows it, the manufacturer's financing programme, government and state relief funds, hospital trust or charity support, and family resources. Each has its own paperwork and its own waiting time, so all of them are started in parallel, at the first appointment.

Six things, all in writing, all before cell collection. Once leukapheresis is done and manufacturing has started, the cost is largely committed and the decision is hard to unwind. The window for questions is before that day.

1. Confirmed eligibility. That diagnosis, CD19 status and prior treatment lines meet the approved indication — stated by the haematologist at the authorised centre.
2. Which centre, and its authorisation. That the centre is authorised for the specific product discussed, and how many CAR-T patients it has treated.
3. A total written estimate. Itemised from leukapheresis to the end of monitoring, with the product on its own line.
4. The insurer's written position. Not a phone assurance — a written response on exclusions, sub-limits, network status and pre-authorisation.
5. Which funding applications are filed, and when. Financing, relief funds and trust support all have lead times, and a dated list keeps them from being remembered too late.
6. The plan if the money runs short mid-pathway. Far better asked in week one than in week six, and every experienced financial counsellor expects it.

Anyone quoting a firm all-in CAR-T figure without seeing your reports, or promising a particular outcome, is not describing how this treatment works. Sourced ranges and a centre's written estimate are the only numbers worth planning around.

CION Cancer Clinics does not provide CAR-T or any other cell therapy, and does not stock, administer or price any CAR-T product. CAR-T in India is delivered at authorised centres with apheresis facilities, cell-manufacturing logistics and the intensive monitoring the treatment requires. A referral to one of those centres is made by your treating haematologist.

What CION centres do provide is day-care immunotherapy and chemotherapy where that is the plan a treating team has arrived at, and orientation material like this page. Those are different things, and the difference matters legally as well as practically.

If you are working through the CAR-T question, the companion pages in this section cover the parts this one does not. Who Is Eligible for NexCAR19? takes the eligibility criteria in detail, which is the question that decides whether cost is even relevant. Indian CAR-T vs Imported: Kymriah, Yescarta and Carvykti sets the domestic products against the imported ones on more than price. Where Is CAR-T Therapy Available in India? covers the authorised-centre map and what to ask a centre. For the wider set of molecule guides, comparisons and cost pages, start from Immunotherapy Medicines Explained, and for how immunotherapy as a whole is used in Indian practice, see the immunotherapy overview.